Effective viral replication is the key in oncolytic virotherapy not only to induce the lytic potential of the virus but also in triggering a systemic immune response against the tumor. We investigated CDK4/6 inhibitors and their effects on the replication of the oncolytic adenovirus XVir-N-31. Bladder cancer cell lines (UMUC3, T24, RT112, 253J, 647V, 639V) were treated with the oncolytic adenovirus XVir-N-31 and/or small molecule inhibitors against Checkpoint kinase 1 (Chk1) (UCN-01, AZD7762) or CDK4/6 (PD-0332991, LEE011, LY-2835219) (CDK4/6i). Cells were infected with viral titers that do not result in cell death were combined with the relative IC 50 of targeted therapies. Cell viability was assessed using a SRB assay and biochemical effects were examined by immunoblotting against E1A, E2A, Hexon, E1B55k, RB, p107, p130, p21, p27, DP1, E2F1-5, Myc, cyclin D1 and E2, ERK and AKT. Virus replication and titer was determined by using qPCR and a titer test on Hek293 cells. siRNAs were used to interfere with E2F1-3 and RB expression level. Effect of E2F binding was examined by cloning different viral vectors modified in E2F binding sites or also E2F trapping mutants. Only the combination of CDK4/6i and XVir-N-31 induced virus specific cell death of 70-90% compared to monotherapy with the inhibitors used. Rb negative cell lines, resistant to PD-0332991, did not show additional effects upon combination treatment. Previously described effects of UCN-01 are due to its ability to also target CDK4/6 but specific CHK-1 inhibition had no effects on virus induced cell death and replication. An increase of 5-10 fold in replication was observed upon use of CDK4/6 inhibitors that decrease the level of RB/E2F1. This modulation induces an earlier and increased transcription of viral genes and was confirmed with viral mutant constructs. Oncolytic adenovirotherapy can be improved in combination with specific CDK4/6 inhibitors by reducing the level of RB/E2F protein complex during early adenoviral life cycle.
Read full abstract